Study analysis · Nature chemical biology · 2023
A new molecule selectively kills leukemia cells by cutting off their energy supply—and it also rewires immune responses.
Scientists created a drug-like molecule that blocks creatine kinases, enzymes cancer cells need for quick energy, killing only those cancers that rely on this system and unexpectedly altering inflammation signals in immune cells.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study was done in a lab using cells and purified proteins, not in people or even animals. It shows that a new chemical can block a specific enzyme and affect how cells grow and respond, but we can't say it would work the same way in a human body because that's a much more complicated system.
What’s the bottom line?
Scientists created a molecule (CKi) that sticks to and blocks a family of enzymes called creatine kinases, which help cells make quick energy. The molecule worked like a key fitting into a lock, as shown by a 3D picture. In cancer cells that rely heavily on this energy system (like some leukemias), the drug stopped their growth and killed them. In immune cells (macrophages), it changed how they produce inflammation signals.
How strong is this study?
The scientists used many careful methods to make sure the chemical only hits its target and not other proteins. They also looked at the structure of the enzyme to see how the chemical binds. That's like taking a high-resolution photo of the lock and key. So, the study is well-designed for the questions it asks, but it only tells us about cells in a dish, not about people.
35 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 547 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an in vitro study using cell lines and biochemical assays. It cannot establish cause-effect relationships in humans. Any causal inferences are limited to the molecular and cellular context studied.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information available in the provided text.
The text does not include any author names, affiliations, or declarations of conflicts of interest or funding sources. The study appears to be basic science research without obvious bias, but full assessment requires additional information.
Key takeaways
- 01
The molecule blocked the enzyme with an IC50 of 1.2 μM.
- 02
In leukemia cells, it lowered the energy molecule phosphocreatine by half at just 1 μM and killed the cells at similar doses (EC50 ~1-10 μM).
- 03
It also reduced production of inflammatory proteins IL-1β and IL-6 but increased TNF-α in immune cells.
- 04
These results are significant because they show a new way to target cancers that use creatine for energy, and also reveal a potential way to control inflammation.
- 05
The molecule is much more selective than previous tools.
Surprising findings
- CKi potentiates TNF-α while inhibiting IL-1β and IL-6 in macrophages, a mixed pro-inflammatory response.It's counterintuitive because blocking a general energy pathway might be expected to suppress all cytokine production, but it selectively remodeled the response.
- CKi is extremely selective, engaging only 4–18 cysteine sites (0.017–0.078% of the observable cysteome) at low micromolar concentrations in cells.Most covalent inhibitors label hundreds of cysteines; this degree of selectivity is exceptional and suggests a highly nucleophilic active-site cysteine in CKs.
Practical takeaways
For researchers: Use CKi as a tool compound to study creatine kinase function in cells, especially in cancer metabolism and immunology.
CKi is not suitable for in vivo use yet due to poor pharmacokinetics; use with careful controls for off-target effects on GSTO1 and GSTCD.
high confidenceFor content creators: Highlight the concept of 'metabolic addiction' in cancer – some cancers become dependent on specific energy pathways.
This is a single study in cell lines and isolated macrophages; human trials are needed before clinical translation.
medium confidenceWhy this study matters
Energy Sabotage: How CKi Starves Cancer Cells
CKi is a covalent inhibitor that targets an active-site cysteine in all four creatine kinase isoforms. It has an IC50 of 1.2 μM against the brain-type creatine kinase (CKB) and depletes cellular phosphocreatine by over 50% at just 1 μM in AML cells within 1 hour, leading to a drop in ATP/ADP ratio.
This shows a new way to target cancer metabolism: by disrupting the creatine-phosphocreatine shuttle that fuels rapid growth, sparing cells that don't depend on this system.
Selective Killing: Only CK-Dependent Cancers Are Vulnerable
CKi and its mitochondrial-targeted analog MitoCKi (IC50 185 nM) are cytotoxic to AML cell lines and patient samples with EC50 ~1-10 μM, while non-CK-dependent cells like A549 are much less sensitive. An analog potency correlation of R²=0.85 confirms on-target cytotoxicity.
This suggests a potential therapeutic window: cancers that overexpress creatine kinases (like some leukemias and metastatic tumors) could be selectively eliminated.
Immune System Remodeling: A Surprising Twist
In macrophages, CKi treatment before LPS stimulation significantly inhibited IL-1β and IL-6 expression but potentiated TNF-α. This was not due to altered TLR signaling (IκBα unaffected). Proteomics revealed increased HMOX1 and decreased CA2 as potential mediators.
This uncovers a previously unknown role of creatine metabolism in controlling inflammation—potentially relevant for autoimmune diseases and sepsis.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists created a molecule (CKi) that sticks to and blocks a family of enzymes called creatine kinases, which help cells make quick energy. The molecule worked like a key fitting into a lock, as shown by a 3D picture. In cancer cells that rely heavily on this energy system (like some leukemias), the drug stopped their growth and killed them. In immune cells (macrophages), it changed how they produce inflammation signals.
Research results
The molecule blocked the enzyme with an IC50 of 1.2 μM. In leukemia cells, it lowered the energy molecule phosphocreatine by half at just 1 μM and killed the cells at similar doses (EC50 ~1-10 μM). It also reduced production of inflammatory proteins IL-1β and IL-6 but increased TNF-α in immune cells.
What this means - more context
These results are significant because they show a new way to target cancers that use creatine for energy, and also reveal a potential way to control inflammation. The molecule is much more selective than previous tools.
To develop a potent and selective covalent inhibitor of creatine kinases (CKs) and evaluate its effects on cancer cell viability and macrophage cytokine production.
A covalent creatine kinase inhibitor (CKi) was developed targeting an active-site cysteine. CKi selectively depletes phosphocreatine, kills CK-dependent AML cells (EC50 ~1-10 μM), and modulates pro-inflammatory cytokine production in macrophages (inhibits IL-1β/IL-6, potentiates TNF-α).
Methods Used
Deep chemoproteomics (CPT-MS) in UCSD-AML1 cells; biochemical assays with recombinant CKB (IC50 1.2 μM); co-crystallography (2.93 Å); metabolomics; viability/apoptosis/cell cycle assays in AML cell lines and patient samples; qPCR and proteomics in mouse BMDMs and human THP1 monocytes.
Main Finding
CKi and MitoCKi selectively inhibit CK activity, deplete phosphocreatine (≥50% depletion at 1 μM), and induce cytotoxicity in CK-dependent AML cells (EC50 ~1-10 μM) with on-target evidence (R²=0.85 for analog potency correlation). In macrophages, CKi reprograms LPS-induced cytokine expression (IL-1β↓, IL-6↓, TNF-α↑).
Confidence Level
High – multiple orthogonal methods (chemoproteomics, crystallography, metabolomics, cellular assays) demonstrate selective CK engagement and on-target effects; correlation between biochemical and cellular potencies supports mechanism.
Study Flags
Red Flags
- •No in vivo efficacy data (pharmacokinetics described as poor for i.v. injection)
- •Limited to preclinical cell and recombinant protein systems
- •Potential off-target engagement of GSTO1 and GSTCD (though low stoichiometry)
Surprising Findings
CKi potentiates TNF-α while inhibiting IL-1β and IL-6 in macrophages, a mixed pro-inflammatory response.
It's counterintuitive because blocking a general energy pathway might be expected to suppress all cytokine production, but it selectively remodeled the response.
Practical Takeaways
For researchers: Use CKi as a tool compound to study creatine kinase function in cells, especially in cancer metabolism and immunology.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 547 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study was done in a lab using cells and purified proteins, not in people or even animals. It shows that a new chemical can block a specific enzyme and affect how cells grow and respond, but we can't say it would work the same way in a human body because that's a much more complicated system.
Strengths
- Deep chemoproteomics with broad cysteine coverage (~40,000 cysteines) to assess selectivity.
- Co-crystal structure of CKi with CKB confirms covalent binding mode.
- Multiple orthogonal assays (activity, metabolite, viability, phosphoproteomics) support conclusions.
Weaknesses
- In vitro only; no in vivo pharmacokinetics or efficacy data.
- Limited cell line diversity for functional studies.
- Potential off-target effects (e.g., GSTO1, GSTCD) not fully characterized for confounding.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists created a molecule (CKi) that sticks to and blocks a family of enzymes called creatine kinases, which help cells make quick energy. The molecule worked like a key fitting into a lock, as shown by a 3D picture. In cancer cells that rely heavily on this energy system (like some leukemias), the drug stopped their growth and killed them. In immune cells (macrophages), it changed how they produce inflammation signals.
Research results
The molecule blocked the enzyme with an IC50 of 1.2 μM. In leukemia cells, it lowered the energy molecule phosphocreatine by half at just 1 μM and killed the cells at similar doses (EC50 ~1-10 μM). It also reduced production of inflammatory proteins IL-1β and IL-6 but increased TNF-α in immune cells.
What this means - more context
These results are significant because they show a new way to target cancers that use creatine for energy, and also reveal a potential way to control inflammation. The molecule is much more selective than previous tools.
To develop a potent and selective covalent inhibitor of creatine kinases (CKs) and evaluate its effects on cancer cell viability and macrophage cytokine production.
A covalent creatine kinase inhibitor (CKi) was developed targeting an active-site cysteine. CKi selectively depletes phosphocreatine, kills CK-dependent AML cells (EC50 ~1-10 μM), and modulates pro-inflammatory cytokine production in macrophages (inhibits IL-1β/IL-6, potentiates TNF-α).
Methods Used
Deep chemoproteomics (CPT-MS) in UCSD-AML1 cells; biochemical assays with recombinant CKB (IC50 1.2 μM); co-crystallography (2.93 Å); metabolomics; viability/apoptosis/cell cycle assays in AML cell lines and patient samples; qPCR and proteomics in mouse BMDMs and human THP1 monocytes.
Main Finding
CKi and MitoCKi selectively inhibit CK activity, deplete phosphocreatine (≥50% depletion at 1 μM), and induce cytotoxicity in CK-dependent AML cells (EC50 ~1-10 μM) with on-target evidence (R²=0.85 for analog potency correlation). In macrophages, CKi reprograms LPS-induced cytokine expression (IL-1β↓, IL-6↓, TNF-α↑).
Confidence Level
High – multiple orthogonal methods (chemoproteomics, crystallography, metabolomics, cellular assays) demonstrate selective CK engagement and on-target effects; correlation between biochemical and cellular potencies supports mechanism.
Study Flags
Red Flags
- •No in vivo efficacy data (pharmacokinetics described as poor for i.v. injection)
- •Limited to preclinical cell and recombinant protein systems
- •Potential off-target engagement of GSTO1 and GSTCD (though low stoichiometry)
Surprising Findings
CKi potentiates TNF-α while inhibiting IL-1β and IL-6 in macrophages, a mixed pro-inflammatory response.
It's counterintuitive because blocking a general energy pathway might be expected to suppress all cytokine production, but it selectively remodeled the response.
Practical Takeaways
For researchers: Use CKi as a tool compound to study creatine kinase function in cells, especially in cancer metabolism and immunology.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 547 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study was done in a lab using cells and purified proteins, not in people or even animals. It shows that a new chemical can block a specific enzyme and affect how cells grow and respond, but we can't say it would work the same way in a human body because that's a much more complicated system.
Strengths
- Deep chemoproteomics with broad cysteine coverage (~40,000 cysteines) to assess selectivity.
- Co-crystal structure of CKi with CKB confirms covalent binding mode.
- Multiple orthogonal assays (activity, metabolite, viability, phosphoproteomics) support conclusions.
Weaknesses
- In vitro only; no in vivo pharmacokinetics or efficacy data.
- Limited cell line diversity for functional studies.
- Potential off-target effects (e.g., GSTO1, GSTCD) not fully characterized for confounding.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists used many careful methods to make sure the chemical only hits its target and not other proteins. They also looked at the structure of the enzyme to see how the chemical binds. That's like taking a high-resolution photo of the lock and key. So, the study is well-designed for the questions it asks, but it only tells us about cells in a dish, not about people.
35 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availabilitycode not shared
19 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 547 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an in vitro study using cell lines and biochemical assays. It cannot establish cause-effect relationships in humans. Any causal inferences are limited to the molecular and cellular context studied.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information available in the provided text.
The text does not include any author names, affiliations, or declarations of conflicts of interest or funding sources. The study appears to be basic science research without obvious bias, but full assessment requires additional information.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr. William Wallace cite this study, drawing 1 claim from it.
- Correlational evidence
The evidence shows a real association, but the studies are observational, so they cannot prove cause and effect. Stronger studies could still change the picture.
Evidence